UNSPSC 51292701: Cilobamine

This classification denotes an antidepressant agent with the molecular formula C17H23CL2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 067U1T4S30 chemically known as bicyclo(2.2.2)octan-2-ol, 2-(3,4-dichlorophenyl)-3-((1-methylethyl)amino)-, cis- but generally known as cilobamine, which bears US NIH Compound Identifier 50538. European Medicines Agency schedules Cilobamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06269MIG.

The term CILOBAMINE is an International Non-Proprietary Name or INN. Most nations schedule cilobamine under HS 29221980 and SITC 51461. As of Q4 2014, CILOBAMINE remains the US FDA Preferred Term for this commodity. Cilobamine bears US NLM identifiers UMLS ID C0621295 and NCI Concept Code C81476. SMILES: CC(C)NC1C2CCC(C1(C3=CC(=C(C=C3)Cl)Cl)O)CC2.

UNSPSC 51292701 Cilobamine, a Commodity code, encompasses pharmaceutical products and drug-related systems that state and local governments procure for public health and community support programs. The recent opportunities posted under this code show solicitations for naloxone and drug deactivation systems, generic pharmaceuticals, and direct-to-manufacturer prescription programs — reflecting a mix of emergency response supplies, routine pharmacy acquisitions, and emerging value-based distribution models. The issuing bodies span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances, indicating that pharmaceutical procurement under this code involves both individual jurisdictions and pooled purchasing vehicles designed to leverage scale across multiple states and localities.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, requiring vendors to handle all shipping costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to supply through three authorized wholesalers with two-year contract terms and 75 percent evaluation weight on price competitiveness. Activity under this code appears concentrated in the Southeast and Midwest, with multi-state cooperative vehicles expanding reach across participating jurisdictions including Minnesota and Oregon.